The Goldman Sachs Group Has Lowered Expectations for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price

The Goldman Sachs Group lowered their price target on shares of Regeneron Pharmaceuticals from $1,019.00 to $917.00 and set a "buy" rating on the stock in a report on Monday.